Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe
about
Antiretroviral drug regimens to prevent mother-to-child transmission of HIV: a review of scientific, program, and policy advances for sub-Saharan AfricaUptake, outcomes, and costs of antenatal, well-baby, and prevention of mother-to-child transmission of HIV services under routine care conditions in ZambiaPoint-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysisEstimating PMTCT's Impact on Heterosexual HIV Transmission: A Mathematical Modeling AnalysisIndividualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survivalLAT software induced savings on medical costs of alcohol addicts' care--results from a matched-pairs case-control studyValidation and calibration of a computer simulation model of pediatric HIV infectionHealth outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in ZambiaCost effectiveness of option B plus for prevention of mother-to-child transmission of HIV in resource-limited countries: evidence from Kumasi, GhanaPrenatal Transmission of Syphilis and Human Immunodeficiency Virus in Brazil: Achieving Regional Targets for EliminationImpact of antiretroviral drugs in pregnant women and their children in Africa: HIV resistance and treatment outcomes.HIV-Infected Ugandan Women on Antiretroviral Therapy Maintain HIV-1 RNA Suppression Across Periconception, Pregnancy, and Postpartum Periods.Bibliometric trends of health economic evaluation in Sub-Saharan Africa.What is needed to eliminate new pediatric HIV infections: the contribution of model-based analyses.Optimizing Antiretroviral Therapy (ART) for Maternal and Child Health (MCH): Rationale and Design of the MCH-ART Study.Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.The survival benefits of antiretroviral therapy in South Africa.The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV.Cost-effectiveness of a package of interventions for expedited antiretroviral therapy initiation during pregnancy in Cape Town, South Africa.Comparative cost-effectiveness of Option B+ for prevention of mother-to-child transmission of HIV in Malawi.Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV: implications for resource-limited countries in sub-Saharan Africa.Option B+ for the prevention of mother-to-child transmission of HIV infection in developing countries: a review of published cost-effectiveness analyses.A risk score to identify HIV-infected women most likely to become lost to follow-up in the postpartum period.Health facility challenges to the provision of Option B+ in western Kenya: a qualitative study.Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand.To B or not to B? That is the question, for global mother-to-child HIV-1 transmission prevention programs.UNICEF's contribution to the adoption and implementation of option B+ for preventing mother-to-child transmission of HIV: a policy analysis.
P2860
Q27014960-01B38221-85C7-4904-8BE8-D2904BF2CB64Q28535891-1C496A24-2E1C-4082-AB19-D18045C50A1EQ28543954-27E579BA-4857-43FF-9B62-24756F7AAFF3Q28547154-9095C4D5-83F4-4922-A08B-F156E5356B4DQ33902803-18954365-7D5C-44DB-B44C-F37CEE2A7EE3Q34472874-189AA8BE-A437-459A-8072-254F60DFC259Q35070944-3C6B79FA-B368-492C-8258-0F38340B4E3DQ35113480-D17347CE-C5C3-4821-A717-ACB13CF61C0BQ35218201-70277C60-B31B-4571-B03B-4598A3A8EC83Q35837696-ACD834CD-EFA1-474E-8940-42734F64BE21Q36852619-18169C50-B4FB-4CCB-B182-E484336590F3Q37092383-A3986F3C-2870-4609-A100-A6A0A0AB85BFQ37203538-5E9FB602-3AC5-45FE-A36E-B5C91CEAE99AQ37238095-B0DC092D-4667-4058-8DBF-202010A80ABAQ37420114-F98C32D7-B6F7-46EE-A02B-5DD21DAC819FQ37508009-20FC513A-9A45-461B-8C77-EEC0AB369703Q37520212-09CC024A-1F00-4703-BFC7-5F849B9921BBQ37630262-F094B5FF-2F82-41A3-9E40-6B2FB156D5ACQ37700076-65148AB1-AEB7-44EA-BB38-76683B5458E6Q37712861-C10964A5-C450-4CFB-A610-201C8A3A212FQ38647745-2F2FBBFD-659B-417C-B97D-D3E7A9E19897Q38789791-D9BBCCE3-B11E-4435-9510-179660E1F09AQ39989882-27C91205-4A03-4077-B67D-4234C2239E0EQ40333108-AE043C64-E3D9-41EC-AB3F-FF66B8C81DDCQ42260621-03E26A47-37C4-4809-B8FE-7F3CB1084CD3Q42284209-E878A7F8-4210-404E-B8F5-5B5F61940EF4Q55077885-59AF28FE-EBB6-4D7B-B1BA-FAD7C57B2EC7
P2860
Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cost-effectiveness of World He ...... d HIV transmission in Zimbabwe
@ast
Cost-effectiveness of World He ...... d HIV transmission in Zimbabwe
@en
type
label
Cost-effectiveness of World He ...... d HIV transmission in Zimbabwe
@ast
Cost-effectiveness of World He ...... d HIV transmission in Zimbabwe
@en
prefLabel
Cost-effectiveness of World He ...... d HIV transmission in Zimbabwe
@ast
Cost-effectiveness of World He ...... d HIV transmission in Zimbabwe
@en
P2093
P2860
P50
P921
P356
P1476
Cost-effectiveness of World He ...... d HIV transmission in Zimbabwe
@en
P2093
Andrea L Ciaranello
Angela Mushavi
Asinath Rusibamayila
Barbara Engelsmann
Ji-Eun Park
Jo Keatinge
Matthews Maruva
Rodrigo Cerda
P2860
P304
P356
10.1093/CID/CIS858
P407
P577
2012-11-30T00:00:00Z